• Integrating New Data From AIDS 2024: Pharmacist Perspectives

  • Aug 30 2024
  • Length: 18 mins
  • Podcast

Integrating New Data From AIDS 2024: Pharmacist Perspectives

Listen for free

View show details

  • Summary

  • In this episode, Jennifer Cocohoba, PharmD, AAHIVP, and David Koren, PharmD, MPH, AAHIVP, FIDSA, cover the most impactful LA ART and LA PrEP clinical studies presented at AIDS 2024, including:

    • The PURPOSE 1 study of twice-yearly lenacapavir injections vs daily oral tenofovir as PrEP in cisgender women
    • An open-label extension of HPTN 084 evaluating LA CAB safety during pregnancy
    • 48-week data from the IMPAACT 2017/MOCHA study of LA CAB + RPV in adolescents with HIV
    • A substudy of FLAIR evaluating the efficacy, safety, and tolerability of SC self-administration of LA CAB + RPV

    Presenters:

    Jennifer Cocohoba, PharmD, AAHIVP
    Professor of Clinical Pharmacy
    Department of Clinical Pharmacy
    University of California San Francisco School of Pharmacy
    San Francisco, California

    David Koren, PharmD, MPH, AAHIVP, FIDSA
    Adjunct Clinical Professor
    Temple University School of Pharmacy
    Clinical Pharmacist Specialist
    Temple University Health System
    Philadelphia, Pennsylvania

    To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

    See the full program here.
    Show more Show less
Show more Show less

What listeners say about Integrating New Data From AIDS 2024: Pharmacist Perspectives

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available